Afatinib Raw Material Powder CAS 439081-18-2

Related Attributes

Product details

Adenosine Raw Material Powder Usage and Synthesis:

Adenosine Raw Material Powder is the first approved irreversible ErbB series blocker. Afatinib has two targets, EGFR and HER2, and can irreversibly block the stimulation of intracellular stimulation caused by the mutation of epidermal growth factor receptor (EGFR) and the overexpression of human epidermal receptor 2 (HER2) tyrosine kinase Abnormal information conduction permanently closes the signal transduction channels that cancer cells rely on to survive, preventing cancer cells from growing and multiplying, thereby treating cancer.

Pharmacokinetics of Adenosine Raw Material Powder :
English name: Afatinib (BIBW2992)
English synonyms: Tovok;BIBW2992;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-( dimethylamino)-2-butenamide;Afatinb;(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)- 4-(dim;Afatinib(cis-transisomerismtautomers);Afatinib(W.S);AFATINIB;BIBW2992;BIBW-2292
CAS number: 439081-18-2
Molecular formula: C24H25ClFN5O3
Molecular weight: 485.94
EINECS No.: 1308068-626-2

Clinical Application of Adenosine Raw Material Powder :
Afatinib is an aminocrotonamido-substituted quinazoline derivative used for the treatment of cancers and diseases of the respiratory tract, lung, gastrointestinal tract, bile duct and gallbladder. These patients are also the group that can benefit most from afatinib treatment in clinical trials. Patients who received afatinib as first-line therapy lived up to a year before their tumors started growing again.

Why choose us?

HRK Factory

About Shipping